AVRN
This asset is not currently listed on any markets available through Pearler. The information on this page may be inaccurate or out of date.
Anteris Technologies Ltd
🇦🇺 ASX
👑 Overview
📈 Performance
💵 Cost
🍃 Esg
🤓 Advanced
👨👩👧👦 Community
📈
N/A
Annual Growth
5 years average annual capital growth
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
0
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
Anteris Technologies Ltd - Ordinary Fully Paid Ex Option Deferred
📈 Performance
Price History
N/A
1M
All Time
Graph
Table
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💵 Costs
💼
N/A
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in AVRN
0
📊 Total Capital Earnings
N/A
🔃 Average investment frequency
N/A
💵 Average investment amount
N/A
⏰ Last time a customer invested in AVRN
N/A
AVRN investor breakdown
💵 Income of investors
More than 200k
150k - 200k
100k - 150k
50k - 100k
Less than 50k
👶 Age of investors
18 - 25
26 - 34
35 - 90
🙋 Legal gender of investors
Female
Male
Pearlers who invest in AVRN also invest in...
Want more shares? Try these...
Anteris Technologies Ltd. is a structural heart company, researches, develops, commercializes, and distributes various medical technologies and devices. The company is headquartered in Toowong, Queensland. The company went IPO on 2004-03-24. The firm is engaged in the manufacture and sale of ADAPT regenerative tissue products globally. The company is focused on developing biomimetic transcatheter aortic valve replacement (TAVR) for the treatment of aortic stenosis. ADAPT is the Company’s patented anti-calcification tissue technology. Its DurAVR THV is a three dimensional (3D) single piece valve and is a biomimetic design that replicates the normal blood flow of a healthy human aortic valve. The firm also provides ComASUR Delivery System, a balloon expandable system with the ability to rotate valves for predictable alignment with the heart’s native commissure.
📊 Share price